Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

Ulz covers the Healthcare sector, focusing on stocks such as Silence Therapeutics, Viking Therapeutics, and IO Biotech. According to TipRanks, Ulz has an average return of 2.7% and a 40.66% success ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

A fortnight off between busy periods for Stoke City as they try to show they are moving in the right direction under another ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

H.C. Wainwright has recently reiterated Viking Therapeutics Inc (VKTX) stock to Buy rating, as announced on November 4, 2024, according to Finviz. Earlier, on September 11, 2024, JP Morgan had ...

NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Voyager Therapeutics (VYGR – Research Report). The ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...